Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03003520
Title A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celgene
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Durvalumab + Lenalidomide + Prednisone + Rituximab + Vincristine Sulfate

Cyclophosphamide + Doxorubicin + Durvalumab + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult | senior
Covered Countries USA | AUT


No variant requirements are available.